An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of chronic venous ulcer (CVU).
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs APZ 2 (Primary)
- Indications Varicose ulcer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors RHEACELL
- 01 Nov 2017 Status changed from recruiting to suspended.
- 16 Oct 2017 Planned initiation date changed from 21 Aug 2017 to 1 Nov 2017.
- 16 Oct 2017 Planned End Date changed from 21 Feb 2019 to 1 Apr 2019.